查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612149

胺基酸代謝紊亂治療市場：按治療、適應症和最終用戶分類 - 全球預測 2025-2030

Amino Acid Metabolism Disorders Treatment Market by Treatment (Gene Therapy, Liver Transplant, Medication), Indication (Maple Syrup Urine Disease, Phenylketonuria), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胺基酸代謝紊亂治療市值為7.969億美元，預計到2024年將達到8.5117億美元，複合年成長率為7.31%，到2030年將達到13.0641億美元。

胺基酸代謝紊亂是一種遺傳性疾病，會影響人體分解或加工胺基酸的能力，而胺基酸是蛋白質的重要組成部分。該市場的治療範圍包括營養食品、酵素替代療法以及旨在調節或補償功能失調的代謝途徑的專用藥物。對此類治療的需求是因為它們有可能預防嚴重的健康問題，例如通常與這些疾病相關的神經病變、發育遲緩和器官功能障礙。應用涵蓋兒科和成人患者群體，重點是早期診斷和長期管理策略。最終用途範圍包括醫院、專科診所和居家照護機構，為受影響的個人提供全面的護理和支援。

主要市場統計
基準年[2023] 7.969 億美元
預計年份 [2024] 85117萬美元
預測年份 [2030] 1,306.41 百萬美元
複合年成長率（%） 7.31%

影響該市場的關鍵成長要素包括代謝紊亂的盛行率日益增加、遺傳和分子診斷的進步以及擴大公私舉措以提高意識和改善治療機會。最近的潛在商機集中在新型治療方法的開發上，特別是針對疾病遺傳根源的基因編輯技術和個人化醫療策略。合成治療性氨基酸和酶的合成生物學研究和創新也可以為業務成長鋪平道路。鼓勵公司投資合作研究夥伴關係並探索市場擴張，特別是在這些治療方法的需求不斷增加的開拓地區。

然而，該市場面臨治療開發成本高、監管挑戰以及對這些疾病的認知低等限制，這可能會抑制市場進入和成長。遺傳疾病的複雜性也對創造普遍有效的治療方法提出了挑戰。為了解決這些限制，對公共教育計畫的策略性投資和支持衛生計劃的遊說至關重要。市場競爭往往強調創新，創造了一個有可能出現專門針對罕見疾病的利基經營模式的環境。公司應專注於尖端研究和開發，與醫療保健提供者合作，並利用技術來最佳化供應鏈效率。

市場動態：揭示快速發展的胺基酸代謝紊亂治療市場的關鍵市場洞察

供需的動態交互作用正在改變胺基酸代謝紊亂治療的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 越來越多的病例被診斷出患有氨基酸代謝紊亂，
    • 加強罕見代謝疾病監管措施
  • 市場限制因素
    • 由於治療費用上漲而限制接觸患者
  • 市場機會
    • 開發增強型診斷工具和基因檢測技術
    • 正在進行的研究旨在發現氨基酸代謝紊亂的新治療方法
  • 市場問題
    • 治療胺基酸代謝紊亂的產品開發的複雜性

波特五力：引領胺基酸代謝紊亂治療市場的策略工具

波特的五力架構是了解胺基酸代謝紊亂治療市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解胺基酸代謝紊亂治療市場的外部影響

外部宏觀環境因素在塑造胺基酸代謝紊亂治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解胺基酸代謝紊亂治療市場的競爭狀況

胺基酸代謝紊亂治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：胺基酸代謝紊亂治療市場供應商的績效評估

FPNV 定位矩陣是評估胺基酸代謝紊亂治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製胺基酸代謝紊亂治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對氨基酸代謝紊亂治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 胺基酸代謝紊亂的診斷不斷增加
      • 加強支持性監管措施以應對罕見代謝疾病
    • 抑制因素
      • 高昂的治療費用限制了患者的就診
    • 機會
      • 開發增強型診斷工具和基因檢測技術
      • 正在進行的研究旨在發現氨基酸代謝紊亂的新治療方法
    • 任務
      • 治療胺基酸代謝紊亂的產品開發的複雜性
  • 市場區隔分析
    • 治療：增加藥物的使用以去除體內多餘的胺基酸
    • 最終使用者：透過醫院和診所擴大胺基酸代謝紊亂治療的可近性，以診斷和治療胺基酸代謝紊亂
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章胺基酸代謝紊亂治療市場：依治療分類

  • 介紹
  • 基因治療
  • 肝臟移植
  • 藥物治療
  • 供應

第7章胺基酸代謝紊亂治療市場：依適應症分類

  • 介紹
  • 楓糖尿症
  • 苯酮尿症

第8章胺基酸代謝紊亂治療市場：依最終使用者分類

  • 介紹
  • 門診手術中心
  • 醫院/診所

第9章北美和南美氨基酸代謝紊亂治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區胺基酸代謝紊亂治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲胺基酸代謝紊亂治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • PTC Therapeutics 在 SSIEM 2023 上展示苯酮尿症治療的新進展
  • 戰略分析和建議

公司名單

  • Abeona Therapeutics Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Gene Therapies
  • Beacon Therapeutics Limited
  • Biogen Inc.
  • Cellectis SA
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-5D693B46BAC2

The Amino Acid Metabolism Disorders Treatment Market was valued at USD 796.90 million in 2023, expected to reach USD 851.17 million in 2024, and is projected to grow at a CAGR of 7.31%, to USD 1,306.41 million by 2030.

Amino acid metabolism disorders are genetic conditions that affect the body's ability to break down or process amino acids, which are essential building blocks of proteins. The scope of treatments in this market includes dietary supplements, enzyme replacement therapies, and specialized medications aimed at regulating or compensating for the dysfunctional metabolic pathways. The necessity for such treatments is driven by their potential to prevent serious health issues such as neurological impairment, developmental delays, and organ dysfunction typically associated with these disorders. Applications extend to both pediatric and adult patient populations, emphasizing early diagnosis and long-term management strategies. The end-use scope includes hospitals, specialty clinics, and homecare settings that provide comprehensive care and support for affected individuals.

KEY MARKET STATISTICS
Base Year [2023] USD 796.90 million
Estimated Year [2024] USD 851.17 million
Forecast Year [2030] USD 1,306.41 million
CAGR (%) 7.31%

Key influencing growth factors in this market include the increasing prevalence of metabolic disorders, advances in genetic and molecular diagnostics, and growing public and private initiatives to improve awareness and treatment access. The latest potential opportunities are centered on the development of novel therapies, especially gene editing technologies and personalized medicine strategies that target the disorder at its genetic root. Research and innovation into synthetic biology to engineer therapeutic amino acids or enzymes can also provide business growth avenues. Companies are recommended to invest in collaborative research partnerships and explore regional market expansions, particularly in underserved areas with rising demand for such treatments.

However, the market faces limitations such as high costs of treatment development, regulatory challenges, and a lack of widespread awareness about these disorders, which can impede market entry and growth. The complexity of genetic conditions also presents challenges in creating universally effective therapies. To address these limitations, strategic investment in public education programs and lobbying for supportive healthcare policies is essential. The nature of the market is competitive with a strong emphasis on innovation, creating fertile ground for niche business models focused on rare diseases. Companies should focus on cutting-edge R&D, partnerships with healthcare providers, and leveraging technology to optimize supply chain efficiencies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amino Acid Metabolism Disorders Treatment Market

The Amino Acid Metabolism Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of diagnosed cases of amino acid metabolism disorders,
    • Enhanced supportive regulatory policies addressing rare metabolic disorders
  • Market Restraints
    • High cost of treatment limiting patient accessibility
  • Market Opportunities
    • Development of enhanced diagnostic tools and genetic testing technologies
    • Ongoing research aimed at discovering new treatments for amino acid metabolism disorders
  • Market Challenges
    • Complexities in product development for amino acid metabolism disorders treatment

Porter's Five Forces: A Strategic Tool for Navigating the Amino Acid Metabolism Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amino Acid Metabolism Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amino Acid Metabolism Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amino Acid Metabolism Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amino Acid Metabolism Disorders Treatment Market

A detailed market share analysis in the Amino Acid Metabolism Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amino Acid Metabolism Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amino Acid Metabolism Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amino Acid Metabolism Disorders Treatment Market

A strategic analysis of the Amino Acid Metabolism Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amino Acid Metabolism Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Gene Therapies, Beacon Therapeutics Limited, Biogen Inc., Cellectis SA, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals, Inc., Merck KGaA, Mustang Bio, Inc., Novartis AG, and Pfizer Inc..

Market Segmentation & Coverage

This research report categorizes the Amino Acid Metabolism Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Gene Therapy, Liver Transplant, Medication, and Supplementation.
  • Based on Indication, market is studied across Maple Syrup Urine Disease and Phenylketonuria.
  • Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of diagnosed cases of amino acid metabolism disorders,
      • 5.1.1.2. Enhanced supportive regulatory policies addressing rare metabolic disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment limiting patient accessibility
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of enhanced diagnostic tools and genetic testing technologies
      • 5.1.3.2. Ongoing research aimed at discovering new treatments for amino acid metabolism disorders
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in product development for amino acid metabolism disorders treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Growing usage of medications to eliminate excess amino acids from the body
    • 5.2.2. End-User: Growing accessibility of amino acid metabolism disorders treatment through hospitals & clinics for diagnosing and treating cases of amino acid metabolism disorders
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amino Acid Metabolism Disorders Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Gene Therapy
  • 6.3. Liver Transplant
  • 6.4. Medication
  • 6.5. Supplementation

7. Amino Acid Metabolism Disorders Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Maple Syrup Urine Disease
  • 7.3. Phenylketonuria

8. Amino Acid Metabolism Disorders Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgery Centers
  • 8.3. Hospitals & Clinics

9. Americas Amino Acid Metabolism Disorders Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Amino Acid Metabolism Disorders Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Amino Acid Metabolism Disorders Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. PTC Therapeutics to Showcase New Advances in Phenylketonuria Treatment at SSIEM 2023
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. American Gene Technologies Inc.
  • 4. Amgen Inc.
  • 5. AnGes, Inc.
  • 6. Astellas Gene Therapies
  • 7. Beacon Therapeutics Limited
  • 8. Biogen Inc.
  • 9. Cellectis SA
  • 10. Editas Medicine, Inc.
  • 11. F. Hoffmann-La Roche Ltd
  • 12. Ionis Pharmaceuticals, Inc.
  • 13. Merck KGaA
  • 14. Mustang Bio, Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY LIVER TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY SUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY MAPLE SYRUP URINE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY PHENYLKETONURIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023